Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3750 - Mutation profiles of nasopharyngeal carcinomas in South-Eastern European patients


09 Oct 2016


Poster display


George Fountzilas


Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376


G. Fountzilas1, A. Psyrri1, E. Giannoulatou2, G. Kouvatseas3, D. Rontogianni1, E. Ciuleanu4, T. Ciuleanu5, L. Resiga4, T. Zaramboukas1, M. Bobos1, S. Chrisafi1, E. Tsolaki1, K. Papadopoulou1, K. Markou1, N. Charalambakis1, A. Koutras1, A. Kalogera-Fountzila1, M. Skondra1, D. Pectasides1, V. Kotoula1

Author affiliations

  • 1 Data Office, Hellenic Cooperative Oncology Group (HeCOG), 11524 - Athens/GR
  • 2 Bioinformatics, Victor Chang Cardiac Research Institute, Darlinghurst/AU
  • 3 Biostatistics, Health Data Specialists Ltd, Athens/GR
  • 4 Radiation, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO
  • 5 Medical Oncology, Ion Chiricuta Oncology Institute-IOCN, 400015 - Cluj Napoca/RO


Abstract 3750


Nasopharyngeal cancer (NPC) is characterized by a remarkable geographical variation and biologic diversity. Importantly, studies investigating mutation profiles of NPC in European populations are scarce.


We investigated the mutational profile of 127 NPC (89% EBV positive) in 93 Greek (GR) and 34 Romanian (RO) patients with locally advanced disease, treated with concomitant chemo-radiotherapy (CCRT) or induction chemotherapy (IC) followed by CCRT. In 19 tumors, dissected matched tumor/lymphocyte (T/L) pairs were compared. Mutation (amino acid changing, minor allele frequency


We identified 1562 mutations in 101/129 tumors (94%). Mutations were mostly found in homologous recombination repair (HRR; 34%), chromatin remodelling (15%) and immune response related (IRR; 10%) genes. In the matched T/L samples, common mutations were identified in 10 cases only, the rest harbouring private mutations. Shared T/L mutations occurred at higher frequencies within the same tumor than T- and L-private mutations (p 


Different genes and sets of genes are affected in stromal and tumor components of NPC, which is important for targeted treatment considerations. Ethnic differences in mutation profiles exist but do not seem to interfere with patient outcome, which seems adversely affected by the absence of EBV and by the presence of BRCA1 mutations.

Clinical trial identification


Legal entity responsible for the study

Hellenic Cooperative Oncology Group


Hellenic Cooperative Oncology Group


G. Fountzilas: Advisory Board: Astra Zeneca S.A. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings